By disrupting both the structural components of cell movement and the regulatory pathways influenced by p53, this integrated therapeutic approach holds promise for effectively reducing metastatic potential and improving treatment outcomes for patients with aggressive cancers. This evidence concerns the gene TP53 and cancer.